Humacyte, Inc. (HUMA), a biotechnology company in the clinical-stage category, declared on Friday its intention to conduct a registered direct offering totaling approximately $30 million in shares and warrants.
The expected gross proceeds from this offering stand at close to $30 million.
In this agreement, Humacyte, Inc. will issue 5.681 million shares along with warrants to acquire an additional 5.681 million shares. The transaction is projected to conclude on or around October 7.
Of these, 2.840 million warrants will be immediately exercisable, carrying an exercise price of $5.28 per share. The cost for acquiring one share coupled with one warrant is set at $5.28.
At the pre-market trading session on Nasdaq, HUMA's stock saw an increase, rising by 5.84 percent, reaching a price of $5.59.
